1. Medicines
  2. Product Updates
  3. Divestments

Divestments

Biosimilars

Erelzi® and Hyrimoz® divestment to Rowez Ltd.

Open
Hospital Brands

Aclasta®, Atriance® and Hycamtin® Solution divestment to Rowex Ltd.

Open
Retail Brands

Estradot®, TransidermNirto® and Hycamtin® capsules divestment to Rowex Ltd.

Open
Rate this content: 
Average: 1 (1 vote)
March 2023 | IE270617
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.